Updated Ph 1b Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients announced; upcoming SUPRAME Ph 3 Trial to be registrational study October 15, 2024
CRLs submitted to request lifting the clinical holds for zevorcabtagene autoleucel, satricabtagene autoleucel and CT071 October 15, 2024
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC October 15, 2024
IV Opdivo Approved in Taiwan in Combination with Cisplatin & Gemcitabine for the 1L Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma October 15, 2024
